John E. Harris
Auto-generated profile, based on publicly available information

John E. Harris

University of Massachusetts Chan Medical School, Worcester, USA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2020 in Annual Review of Immunology
Verified
Journal Article
Closed access
MFMichael L. Frisoli
Michael L. Frisoli
KEKingsley Essien
Kingsley Essien
JHJohn E. Harris
John E. Harris
Vitiligo is an autoimmune disease of the skin that targets pigment-producing melanocytes and results in patches of depigmentation that are visible as white spots. Recent research studies have yielded a strong mechanistic understanding of this disease. Autoreactive cytotoxic CD8+T cells engage melanocytes and promote disease progression through the local production of IFN-γ, and IFN-γ-induced chemokines are then secreted from surrounding keratinocytes to further recruit T cells to the skin through a positive-feedback loop. Both topical and systemic treatments that block IFN-γ signaling can effectively reverse vitiligo in humans; however, disease relapse is common after stopping treatments. Autoreactive resident memory T cells are responsible for relapse, and new treatment strategies focus on eliminating these cells to promote long-lasting benefit. Here, we discuss basic, translational, and clinical research studies that provide insight into the pathogenesis of vitiligo, and how this insight has been utilized to create new targeted treatment strategies.

12 February 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MRMehdi Rashighi
Mehdi Rashighi
PAPriti Agarwal
Priti Agarwal
JRJillian M. Richmond
Jillian M. Richmond
THTajie H. Harris
Tajie H. Harris
KDKaren Dresser
Karen Dresser
JHJohn E. Harris
John E. Harris
Vitiligo is an autoimmune disease of the skin that results in disfiguring white spots. There are no U.S. Food and Drug Administration–approved treatments for vitiligo, and most off-label treatments yield unsatisfactory results. Vitiligo patients have increased numbers of autoreactive, melanocyte-specific CD8+ T cells in the skin and blood, which are directly responsible for melanocyte destruction. We report that gene expression in lesional skin from vitiligo patients revealed an interferon-γ (IFN-γ)–specific signature, including the chemokine CXCL10. CXCL10 was elevated in both vitiligo patient skin and serum, and CXCR3, its receptor, was expressed on pathogenic T cells. To address the function of CXCL10 in vitiligo, we used a mouse model of disease that also exhibited an IFN-γ–specific gene signature, expression of CXCL10 in the skin, and up-regulation of CXCR3 on antigen-specific T cells. Mice that received Cxcr3−/− T cells developed minimal depigmentation, as did mice lacking Cxcl10 or treated with CXCL10-neutralizing antibody. CXCL9 promoted autoreactive T cell global recruitment to the skin but not effector function, whereas CXCL10 was required for effector function and localization within the skin. Surprisingly, CXCL10 neutralization in mice with established, widespread depigmentation induces reversal of disease, evidenced by repigmentation. These data identify a critical role for CXCL10 in both the progression and maintenance of vitiligo and thereby support inhibiting CXCL10 as a targeted treatment strategy.

1 July 2012 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
JHJohn E. Harris
John E. Harris
THTajie H. Harris
Tajie H. Harris
WWWolfgang Weninger
Wolfgang Weninger
EWE. John Wherry
E. John Wherry
CHChristopher A. Hunter
Christopher A. Hunter
LTLaurence A. Turka
Laurence A. Turka

18 July 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JRJillian M. Richmond
Jillian M. Richmond
JSJames P. Strassner
James P. Strassner
LZLucio Zapata
Lucio Zapata
MGMadhuri Garg
Madhuri Garg
RRRebecca L. Riding
Rebecca L. Riding
JHJohn E. Harris
John E. Harris
Vitiligo is an autoimmune disease of the skin mediated by CD8+ T cells that kill melanocytes and create white spots. Skin lesions in vitiligo frequently return after discontinuing conventional treatments, supporting the hypothesis that autoimmune memory is formed at these locations. We found that lesional T cells in mice and humans with vitiligo display a resident memory (TRM) phenotype, similar to those that provide rapid, localized protection against reinfection from skin and mucosal-tropic viruses. Interleukin-15 (IL-15)–deficient mice reportedly have impaired TRM formation, and IL-15 promotes TRM function ex vivo. We found that both human and mouse TRM express the CD122 subunit of the IL-15 receptor and that keratinocytes up-regulate CD215, the subunit required to display the cytokine on their surface to promote activation of T cells. Targeting IL-15 signaling with an anti-CD122 antibody reverses disease in mice with established vitiligo. Short-term treatment with anti-CD122 inhibits TRM production of interferon-γ (IFNγ), and long-term treatment depletes TRM from skin lesions. Short-term treatment with anti-CD122 can provide durable repigmentation when administered either systemically or locally in the skin. On the basis of these data, we propose that targeting CD122 may be a highly effective and even durable treatment strategy for vitiligo and other tissue-specific autoimmune diseases involving TRM.

1 October 2017 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
LLLucy Y. Liu
Lucy Y. Liu
JSJames P. Strassner
James P. Strassner
MRMaggi A. Refat
Maggi A. Refat
JHJohn E. Harris
John E. Harris
BKBrett A. King
Brett A. King

1 February 2017 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JRJillian M. Richmond
Jillian M. Richmond
DBDinesh S. Bangari
Dinesh S. Bangari
KEKingsley I. Essien
Kingsley I. Essien
SCSharif D. Currimbhoy
Sharif D. Currimbhoy
JGJoanna R. Groom
Joanna R. Groom
JHJohn E. Harris
John E. Harris